Biology Reference
In-Depth Information
Table 1
continued)
Description
POD 21
POD 28
Pro-angiogenic
Mock
RCMV
Mock
RCMV
M-CSF I receptor
3.07
6.38
3.86
11.31*
CSF 2 receptor, beta 1 (gran-mac)
3.27
5.21
4.14
6.59
Matrix metalloproteinase 3
2.13
2.39
2.30
4.86
Matrix metalloproteinase 12
17.23
4.17
8.46
367.09*
Matrix metalloproteinase 14
8.63
4.20
3.37
11.00*
Matrix metalloproteinase 23
4.51
3.29
3.32
6.19
Plasminogen activator inhibitor 2 type A
1.55
2.08
1.80
2.93
Ser (or cys) proteinase inhibitor, member 1
8.88
10.34
15.03
20.39
Plasminogen activator, urokinase
6.62
12.91*
9.36
65.34*
Plasminogen activator, urokinase receptor
3.46
5.98
3.85
12.38*
Platelet-derived growth factor, C
2.36
2.48
2.47
3.89*
Transforming growth factor, beta 1
2.96
4.69
3.93
9.78*
Transforming growth factor, beta 2
6.57
10.85
13.96
4.69
Transforming growth factor, beta receptor 1
3.61
5.78*
4.73
6.36*
Transforming growth factor, beta receptor 2
3.95
5.90
4.38
6.45*
Bone morphogenetic protein 2
4.24
5.78
5.00
6.82
Bone morphogenetic protein 7
3.57
3.89
3.89
3.73
Growth differentiation factor 15
3.03
2.83
4.62
5.17
Lymphotoxin A
3.71
5.17*
6.28
5.10*
TNF superfamily member 6
3.96
11.71*
6.77
17.88*
TNF superfamily member 11
2.50
3.66
2.97
3.92*
TNF superfamily member 13
4.71
12.04*
7.05
17.88*
TNF receptor superfamily member 1b
3.71
11.08*
6.53
13.83*
TNF receptor superfamily member 4
3.47
8.75
6.13
10.48
TNF receptor superfamily member 11b
3.96
18.64*
5.10
40.22*
TNF receptor superfamily member 12a
5.72
7.46
8.32
4.03
Vascular endothelial growth factor D
3.33
3.33
3.26
3.18
fms-related tyrosine kinase 4
3.99
3.56
3.75
3.92
Anti-Angiogenic
Interferon gamma
1.64
4.79*
4.33
10.78*
Interleukin 4 receptor
3.11
6.32*
3.69
6.02*
Interleukin 10
1.38
3.07*
2.11
3.86*
Interleukin 12b
3.65
5.35
4.54
3.58
Chemokine (C-X-C motif) ligand 10
28.49
222.51*
143.15
178.07*
Thrombospondin 2
5.95*
2.93
3.05
5.24
Tissue inhibitor of metalloproteinase 1
17.75
33.59
33.75
41.64
Tissue inhibitor of metalloproteinase 2
2.33
1.53
1.67
3.41*
in vitro
, HCMV infects all of these cell types, and aside from immunologic clear-
ance, viral infection modifies many of the host cellular functions that promote
tissue repair. For example, CMV infection resulting in acceleration of CR is the
increase in the host immune response to the allograft and the virus resulting in
recruitment of inflammatory cells, and inflammatory effectors such as chemokines
and cytokines including interferon-gamma (IFN-
γ
), TNF-
α
, interleukin-4 (IL-4),
IL-18, RANTES, MCP-1, MIP-1
, IL-8, and IP-10 (Almeida et al. 1994; Almeida-
Porada et al. 1997; Vieira et al. 1998; Humar et al. 1999; Streblow et al. 1999, 2003;
α
